MEI Pharma to Consider Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Brookline Capital Markets Downgrades MEI Pharma (MEIP) to Hold
July 22, 2024 11:52 AM EDTBrookline Capital Markets analyst Leah Rush Cann downgraded MEI Pharma (NASDAQ: MEIP) from Buy to Hold.
The analyst comments "We cover MEI Pharma, a development-stage biotechnology company working in the PI3K pathway, CDK inhibition, epigenetics, and cancer metabolism, and... More
